The oncostatin M signalling pathway: reversing the neoplastic phenotype?

Oncostatin M (OSM) is a member of the interleukin 6 (IL-6) family of cytokines and was originally identified by its ability to inhibit proliferation of melanoma cells but augment the growth of normal fibroblasts. OSM has pleiotropic effects on many different cell types, but here we focus on its abil...

Full description

Saved in:
Bibliographic Details
Published in:Molecular Medicine Today 1999-09, Vol.5 (9), p.406-412
Main Authors: Grant, Susan L., Begley, C.Glenn
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - metabolism
Antineoplastic Agents - pharmacology
Cancer
Cytokine
Humans
Neoplasms - therapy
Oncostatin M
Peptides - metabolism
Peptides - pharmacology
Peptides - physiology
Phenotype
Receptor
Signal Transduction - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncostatin M (OSM) is a member of the interleukin 6 (IL-6) family of cytokines and was originally identified by its ability to inhibit proliferation of melanoma cells but augment the growth of normal fibroblasts. OSM has pleiotropic effects on many different cell types, but here we focus on its ability to inhibit the proliferation of cell lines derived from several tumour types, including breast carcinoma, ovarian cancer, melanoma, glioma and lung carcinoma. The inhibition of proliferation of several cancer cell lines by OSM is associated with alterations in cellular morphology and with phenotypic changes that are consistent with the induction of differentiation of these cells. These observations raise the possibility that OSM could have therapeutic potential.
ISSN:1357-4310
DOI:10.1016/S1357-4310(99)01540-3